help ADVANCE RESEARCH on MDMA THERAPY for PTSD

Pneuma Science is partnering with Dr. Jamarie Geller to raise funds for a groundbreaking, international study on MDMA-assisted psychotherapy (MDMA-AP) for post-traumatic stress disorder (PTSD).

This project will evaluate patient access, safety, and treatment outcomes in one of the world’s first clinics legally offering MDMA-AP as part of standard medical care—bridging the gap between clinical trials and real-world practice.

Organized by:
Dr. Jamarie Geller, MD
Chief Clinical Officer

$7,801

Funds Raised

$15,000

Total Goal

SEP 15

Target Date

About This Project

This fund supports Dr. Jamarie (“Jamo”) Geller, Chief Clinical Officer at Pneuma Science, in a groundbreaking international collaboration to evaluate MDMA-assisted psychotherapy (MDMA-AP) for post-traumatic stress disorder (PTSD).

Dr. Geller will partner with one of the world’s first clinics legally offering MDMA-AP as part of standard medical care. This project will generate publishable, real-world data on outcomes, safety, and accessibility of this novel treatment.

While PTSD is common and often devastating, many current treatments remain insufficient. Clinical trials in the U.S. show that MDMA-AP can be safe and effective, yet the FDA has declined approval. In contrast, Australia has legalized MDMA-AP under regulated conditions, creating a unique opportunity to study this therapy in practice.

Because traditional funding channels rarely support this type of early, applied research, we are seeking community support. Every gift will be matched 1:1, doubling your impact.

WHAT THIS PROJEC WILL DO.

  • Publish the first real-world data on MDMA therapy for PTSD in a legal clinical setting

  • Evaluate outcomes, safety, and accessibility outside controlled trial conditions

  • Develop ethical guidance for responsible delivery, especially for vulnerable populations

  • Foster global collaboration to guide safe adoption of psychedelic treatments

WHY THIS MATTERS.

PTSD affects millions worldwide, contributing to disability, suffering, and healthcare burden. Despite advances, many patients fail to respond adequately to existing therapies. High-quality evidence on how psychedelic-assisted therapies function in routine care is urgently needed to guide safe, equitable, and effective implementation.

This study is unique because it examines real-world clinical practice under an existing legal framework, providing insights that clinical trials alone cannot.

Why give?

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.

  • ✽

    It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more.